T Cell Redirect and Anti-CD44 Therapy for AML
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) and multiple myeloma (MM) face challenges in achieving long-term remission due to the persistence of cancer stem cells and the immunosuppressive nature of the bone marrow niche, which impairs the efficacy of T cell redirection therapies.
Innovation Solution
A pharmaceutical composition comprising a T cell redirection therapeutic and an anti-CD44 therapeutic, where the T cell redirection therapeutic is a bispecific antibody binding to both T cell surface antigen CD3 and tumor-associated antigen CD123, and an anti-CD44 antibody or fragment is used to disrupt the protective interactions between cancer cells and bone marrow stromal cells, enhancing T cell cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell redirection therapy is used to kill cancer cells, then tumor cell lysis is improved, but the immunosuppressive bone marrow niche protects cancer stem cells from therapy
Solution Approach 1:
The patent introduces an anti-CD44 antibody as an intermediary agent that blocks the protective interaction between cancer stem cells and bone marrow stromal cells. This mediator disrupts the immunosuppressive niche without directly killing tumor cells, allowing T cell redirection therapy to work more effectively against protected cancer stem cells.
Solution Approach 2:
The patent extracts or removes the protective effect of the bone marrow niche by targeting CD44 on stromal cells. By eliminating this protective mechanism through anti-CD44 therapy, the cancer stem cells are no longer shielded from T cell-mediated cytotoxicity, thereby improving overall treatment efficacy.
2Reliability
If combination therapy with T cell redirection and anti-CD44 is used, then cytotoxicity is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges two therapeutic mechanisms into a single combination therapy: T cell redirection (via bispecific antibody engaging CD3 and tumor antigen) and stromal cell disruption (via anti-CD44 antibody). This combination synergistically enhances cytotoxicity by simultaneously activating T cells and removing protective niche effects, while maintaining manageable complexity through targeted molecular approaches.
Data Source
AI summary
Disclosed herein is a pharmaceutical composition comprising a T cell redirect therapeutic and an anti-CD44 therapeutic, and uses thereof for killing cancer cells.